Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron vs. Adefovir in HBeAg-Positive Chronic Hepatitis B
NCT00371761Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Primary completion
- Feb 2009
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by Merck & Co. Primary endpoint: Combined Serological, Virological, and Biochemical Response at 72 weeks. Started Sep 2006; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00371761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00371761.